Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
neurological disorders
Biotech
Third Rock, J&J neuroscience spinout Rapport arrives with $100M
Rapport Therapeutics is launching with $100 million in funding and a clinical-stage neuroscience asset born in Johnson & Johnson’s labs.
James Waldron
Mar 7, 2023 9:05am
Tourette-focused Emalex rakes in $250M series D
Nov 3, 2022 7:00am
Astellas continues gene therapy push with $50M stake in Taysha
Oct 24, 2022 7:30pm
Biohaven flunks ALS trial, the 2nd gut punch since Nurtec sale
Sep 29, 2022 10:30am
BrainStorm asks for ALS approval 1 year after FDA spiked data
Aug 15, 2022 12:28pm
Brain immune cells 'listen in' to neurons
Aug 12, 2022 5:30am
